These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 24395923)

  • 1. Genetic variants in CCNB1 associated with differential gene transcription and risk of coronary in-stent restenosis.
    Silvestre-Roig C; Fernández P; Mansego ML; van Tiel CM; Viana R; Anselmi CV; Condorelli G; de Winter RJ; Martín-Fuentes P; Solanas-Barca M; Civeira F; Focaccio A; de Vries CJ; Chaves FJ; Andrés V
    Circ Cardiovasc Genet; 2014 Feb; 7(1):59-70. PubMed ID: 24395923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p27kip1-838C>A single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kip1 promoter activity.
    van Tiel CM; Bonta PI; Rittersma SZ; Beijk MA; Bradley EJ; Klous AM; Koch KT; Baas F; Jukema JW; Pons D; Sampietro ML; Pannekoek H; de Winter RJ; de Vries CJ
    Circulation; 2009 Aug; 120(8):669-76. PubMed ID: 19667240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Gene Polymorphisms/Haplotypes and Plasma Level of TGF-β1 in Susceptibility to In-Stent Restenosis Following Coronary Implantation of Bare Metal Stent in Chinese Han Patients.
    Chen HJ; Mo N; Zhang YF; Su GZ; Wu HD; Pei F
    Int Heart J; 2018 Jan; 59(1):161-169. PubMed ID: 29332922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
    Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 677TT polymorphism of methylenetetrahydrofolate reductase in combination with low serum vitamin B12 is associated with coronary in-stent restenosis.
    Chung SL; Chiou KR; Charng MJ
    Catheter Cardiovasc Interv; 2006 Mar; 67(3):349-55. PubMed ID: 16489563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions.
    Rudez G; Pons D; Leebeek F; Monraats P; Schrevel M; Zwinderman A; de Winter R; Tio R; Doevendans P; Jukema W; de Maat M
    Hum Mutat; 2008 Mar; 29(3):375-80. PubMed ID: 18175333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interleukin 1B-511 polymorphism is associated with the risk of developing restenosis after coronary stenting in Mexican patients.
    Miranda-Malpica E; Martínez-Rios MA; Fragoso JM; Delgadillo-Rodríguez H; Rodríguez-Pérez JM; González-Quesada C; Martínez-Rodríguez N; Saldaña-Mendoza A; Peña-Duque MA; Vargas-Alarcón G
    Hum Immunol; 2008 Feb; 69(2):116-21. PubMed ID: 18361937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proximal coronary artery intervention: stent thrombosis, restenosis and death.
    Calais F; Lagerqvist B; Leppert J; James SK; Fröbert O
    Int J Cardiol; 2013 Dec; 170(2):227-32. PubMed ID: 24211065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]).
    Alfonso F; Pérez-Vizcayno MJ; Dutary J; Zueco J; Cequier A; García-Touchard A; Martí V; Lozano I; Angel J; Hernández JM; López-Mínguez JR; Melgares R; Moreno R; Seidelberger B; Fernández C; Hernandez R;
    JACC Cardiovasc Interv; 2012 Jul; 5(7):728-37. PubMed ID: 22814777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and study design of the CardioGene Study: genomics of in-stent restenosis.
    Ganesh SK; Skelding KA; Mehta L; O'Neill K; Joo J; Zheng G; Goldstein J; Simari R; Billings E; Geller NL; Holmes D; O'Neill WW; Nabel EG
    Pharmacogenomics; 2004 Oct; 5(7):952-1004. PubMed ID: 15469413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The T29C (rs1800470) polymorphism of the transforming growth factor-β1 (TGF-β1) gene is associated with restenosis after coronary stenting in Mexican patients.
    Fragoso JM; Zuñiga-Ramos J; Arellano-González M; Alvarez-León E; Villegas-Torres BE; Cruz-Lagunas A; Delgadillo-Rodriguez H; Peña-Duque MA; Martínez-Ríos MA; Vargas-Alarcón G
    Exp Mol Pathol; 2015 Feb; 98(1):13-7. PubMed ID: 25449332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
    Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention.
    Beijk MA; Boekholdt SM; Rittersma SZ; Pons D; Zwinderman AH; Doevendans PA; Tio RA; Tijssen JG; Jukema JW; de Winter RJ
    Pharmacogenet Genomics; 2010 Sep; 20(9):544-52. PubMed ID: 20671584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
    Brodie BR; Wilson H; Stuckey T; Nussbaum M; Laurent S; Bradshaw B; Humphrey A; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Simonton CA;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1105-12. PubMed ID: 19926052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rs1803274 polymorphism of the BCHE gene is associated with an increased risk of coronary in-stent restenosis.
    Pleva L; Kovarova P; Faldynova L; Plevova P; Hilscherova S; Zapletalova J; Kusnierova P; Kukla P
    BMC Cardiovasc Disord; 2015 Oct; 15():135. PubMed ID: 26497592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and procedural predictors of suboptimal outcome after the treatment of drug-eluting stent restenosis in the unprotected distal left main stem: the Milan and New-Tokyo (MITO) registry.
    Takagi K; Ielasi A; Shannon J; Latib A; Godino C; Davidavicius G; Mussardo M; Ferrarello S; Figini F; Carlino M; Montorfano M; Chieffo A; Nakamura S; Colombo A
    Circ Cardiovasc Interv; 2012 Aug; 5(4):491-8. PubMed ID: 22851528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.